STOCK TITAN
  1. Home
  2. Sec-filings
  3. COYA
  4. [8-K] Coya Therapeutics, Inc. Reports Material Event

Coya Therapeutics (NASDAQ: COYA) shareholders back board nominees and 2026 auditor

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Coya Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 25, 2026. Stockholders elected two Class I directors to new three-year terms and ratified the company’s independent auditor for the 2026 fiscal year.

Secretary Wilbur Ross received 9,168,496 votes for and 2,818,233 withheld, with 4,585,732 broker non-votes. Dieter Weinand received 10,566,702 votes for and 1,420,027 withheld, with the same 4,585,732 broker non-votes. Stockholders also ratified Weaver and Tidwell, L.L.P. as the independent registered public accounting firm with 16,545,887 votes for, 22,661 against, and 3,913 abstentions.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Wilbur Ross 9,168,496 votes Election as Class I director at June 25, 2026 annual meeting
Votes withheld Wilbur Ross 2,818,233 votes Election as Class I director at June 25, 2026 annual meeting
Votes for Dieter Weinand 10,566,702 votes Election as Class I director at June 25, 2026 annual meeting
Votes withheld Dieter Weinand 1,420,027 votes Election as Class I director at June 25, 2026 annual meeting
Broker non-votes on director election 4,585,732 votes Director election proposals at annual meeting
Votes for auditor ratification 16,545,887 votes Ratification of Weaver and Tidwell, L.L.P. for 2026
Votes against auditor ratification 22,661 votes Ratification of Weaver and Tidwell, L.L.P. for 2026
Abstentions on auditor ratification 3,913 votes Ratification of Weaver and Tidwell, L.L.P. for 2026
broker non-votes financial
"The votes were cast for this matter were as follows ... Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Emerging growth company regulatory
"Emerging growth company    On June 25, 2026, Coya Therapeutics, Inc."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Annual Meeting of Stockholders financial
"held its Annual Meeting of Stockholders (the “Annual Meeting”)"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001835022 0001835022 2026-06-25 2026-06-25
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2026

 

 

Coya Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41583   85-4017781

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

5850 San Felipe St., Suite 500

Houston, Texas 77057

(Address of principal executive offices, including zip code)

(800) 587-8170 (Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 § CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 § CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR § 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR § 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:

  

Trading
Symbol

  

Name of Each Exchange

on which Registered

Common Stock, par value $0.0001 per share   COYA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 25, 2026, Coya Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were: (i) the election of two Class I directors and (ii) the ratification of the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows:

1. The election of Secretary Wilbur Ross and Dieter Weinand, as Class I directors to hold office for a term of three years, until their successors are duly elected and qualified or they are otherwise unable to complete their respective terms. The votes were cast for this matter were as follows:

 

Nominee

    For    Withheld    Broker Non-Votes

Secretary Wilbur Ross

     9,168,496    2,818,233    4,585,732

Dieter Weinand

    10,566,702    1,420,027    4,585,732

2. The proposal to ratify the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes:

 

For   Against   Abstain
16,545,887   22,661   3,913

 

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    COYA THERAPEUTICS, INC.
Dated: June 25, 2026     By:  

/s/ Arun Swaminathan Ph.D.

      Arun Swaminathan
      Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Coya Therapeutics (COYA) stockholders approve at the June 25, 2026 meeting?

Stockholders elected two Class I directors and ratified the external auditor. Secretary Wilbur Ross and Dieter Weinand were elected to three-year terms, and Weaver and Tidwell, L.L.P. was confirmed as independent registered public accounting firm for the fiscal year ending December 31, 2026.

How many votes did Coya Therapeutics director nominee Wilbur Ross receive?

Secretary Wilbur Ross received 9,168,496 votes for election and 2,818,233 votes withheld. There were also 4,585,732 broker non-votes recorded for this proposal, which represent shares present but not voted on the director item by certain intermediaries.

How many votes did Coya Therapeutics director nominee Dieter Weinand receive?

Dieter Weinand received 10,566,702 votes for election and 1,420,027 votes withheld. As with the other director nominee, there were 4,585,732 broker non-votes, meaning some beneficially owned shares were not instructed on the director proposal by their brokers.

What were the auditor ratification voting results for Coya Therapeutics (COYA)?

Stockholders strongly supported ratifying Weaver and Tidwell, L.L.P. as auditor, with 16,545,887 votes for, 22,661 against, and 3,913 abstentions. This confirms the firm as Coya Therapeutics’ independent registered public accounting company for the fiscal year ending December 31, 2026.

What is the term length for the Class I directors elected at Coya Therapeutics’ 2026 meeting?

The Class I directors, Secretary Wilbur Ross and Dieter Weinand, will each serve a three-year term. They hold office until their successors are duly elected and qualified or until they are otherwise unable to complete their respective terms as directors.

Filing Exhibits & Attachments

3 documents

Other Documents